Showing 7661-7670 of 9147 results for "".
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the
- Coral-friendly Sunscreen Provides Better UV Protection Than Existing Optionshttps://practicaldermatology.com/news/coral-friendly-sunscreen-provides-better-uv-protection-than-existing-options/2461584/A new coral-friendly polymeric UV filter may be more effective at preventing sunburn than existing sunscreens. Researchers used polymerization to create large molecules that still block UV radiation but are too big to penetrate our skin, coral, and algae. The study was p
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with
- Incyte Receives Positive CHMP Opinion for Opzelura Cream for the Treatment of Non-Segmental Vitiligohttps://practicaldermatology.com/news/incyte-receives-positive-chmp-opinion-for-opzelura-cream-for-the-treatment-of-non-segmental-vitiligo/2461576/The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Exosome Update: Evolve Skincare to Distribute Elevai Skin Care Products in Canadahttps://practicaldermatology.com/news/exosome-update-evolve-skincare-to-distribute-elevai-skin-care-products-in-canada/2461572/Evolve Medical Inc. is the exclusive distributor for Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- La Roche-Posay Gives Back: Brand Supports USC's Skin of Color and Pigmentary Disorders Research Fellowshiphttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-supports-uscs-skin-of-color-and-pigmentary-disorders-research-fellowship/2461558/La Roche-Posay is supporting the Skin of Color and Pigmentary Disorders Research Fellowship at the Keck School of Medicine of University of Southern California (USC). The fellowship allows students, between their third and fourth years of medical school, the opportunity to con